具有抗癌活性的Mg(II)半胱氨酸二硫代氨基甲酸酯配合物的新应用前景。

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-239006

Indah Raya, Desy Kartina, Rizal Irfandi, Sandi Sufiandi, Ronald Ivan Wijaya, Prihantono Prihantono, Eid A Abdalrazaq, Mahmoud Kandeel, Andi Nilawati Usman

{"title":"具有抗癌活性的Mg(II)半胱氨酸二硫代氨基甲酸酯配合物的新应用前景。","authors":"Indah Raya, Desy Kartina, Rizal Irfandi, Sandi Sufiandi, Ronald Ivan Wijaya, Prihantono Prihantono, Eid A Abdalrazaq, Mahmoud Kandeel, Andi Nilawati Usman","doi":"10.3233/BD-239006","DOIUrl":null,"url":null,"abstract":"Objective: The new Mg(II) cysteindithiocarbamate complex drug has been synthesized by the in-situ method and tested for its anticancer activity in vitro.Method: Mg(II) cysteindithiocarbamate complexes were characterized using Ultra Violet Visible, Infra-Red, melting points, and molar conductivity.Results: The UV-Vis data of cysteindithiocarbamate Mg(II), shows that at 296 nm and 385 nm was occurred the electronic transitions π → π* and n → π* for CS2 and N =C =S. Whereas the IR data at wavelengths in the 393-540 cm-1 shows that there has coordinated between Mg(II) with Sulfur (S), Nitrogen (N), and Oxygen (O) atoms from cysteinedithiocarbamate ligands.Conclusion: The cytotoxicity test results showed that the Mg complex's cytotoxicity was higher than that of the cytotoxicity of the Mg metal without ligands, which means that the Mg complex can be developed as a potential new anticancer drug.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"177-182"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The new potential application for Mg(II) cysteinedithiocarbamate complex with anticancer activity.\",\"authors\":\"Indah Raya, Desy Kartina, Rizal Irfandi, Sandi Sufiandi, Ronald Ivan Wijaya, Prihantono Prihantono, Eid A Abdalrazaq, Mahmoud Kandeel, Andi Nilawati Usman\",\"doi\":\"10.3233/BD-239006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The new Mg(II) cysteindithiocarbamate complex drug has been synthesized by the in-situ method and tested for its anticancer activity in vitro.Method: Mg(II) cysteindithiocarbamate complexes were characterized using Ultra Violet Visible, Infra-Red, melting points, and molar conductivity.Results: The UV-Vis data of cysteindithiocarbamate Mg(II), shows that at 296 nm and 385 nm was occurred the electronic transitions π → π* and n → π* for CS2 and N =C =S. Whereas the IR data at wavelengths in the 393-540 cm-1 shows that there has coordinated between Mg(II) with Sulfur (S), Nitrogen (N), and Oxygen (O) atoms from cysteinedithiocarbamate ligands.Conclusion: The cytotoxicity test results showed that the Mg complex's cytotoxicity was higher than that of the cytotoxicity of the Mg metal without ligands, which means that the Mg complex can be developed as a potential new anticancer drug.\",\"PeriodicalId\":9224,\"journal\":{\"name\":\"Breast disease\",\"volume\":\"42 1\",\"pages\":\"177-182\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/BD-239006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-239006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的:原位合成新型半胱氨酸二硫代氨基甲酸镁配合物，并进行体外抗癌活性测定。方法:采用紫外可见光谱、红外光谱、熔点、摩尔电导率等方法对半胱氨酸二硫代氨基甲酸镁配合物进行表征。结果:半胱氨酸硫代氨基甲酸酯Mg(II)的紫外可见光谱表明，CS2在296 nm和385 nm处发生π→π*和n→π*电子跃迁，n =C =S。而393 ~ 540 cm-1波段的红外数据表明，Mg(II)与半胱氨酸二硫代氨基甲酸酯配体中的硫(S)、氮(N)和氧(O)原子之间存在配位。结论:细胞毒性试验结果表明，Mg配合物的细胞毒性高于不含配体的金属Mg的细胞毒性，这意味着Mg配合物可以作为一种潜在的新型抗癌药物开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The new potential application for Mg(II) cysteinedithiocarbamate complex with anticancer activity.

Objective: The new Mg(II) cysteindithiocarbamate complex drug has been synthesized by the in-situ method and tested for its anticancer activity in vitro.

Method: Mg(II) cysteindithiocarbamate complexes were characterized using Ultra Violet Visible, Infra-Red, melting points, and molar conductivity.

Results: The UV-Vis data of cysteindithiocarbamate Mg(II), shows that at 296 nm and 385 nm was occurred the electronic transitions π → π* and n → π* for CS2 and N =C =S. Whereas the IR data at wavelengths in the 393-540 cm-1 shows that there has coordinated between Mg(II) with Sulfur (S), Nitrogen (N), and Oxygen (O) atoms from cysteinedithiocarbamate ligands.

Conclusion: The cytotoxicity test results showed that the Mg complex's cytotoxicity was higher than that of the cytotoxicity of the Mg metal without ligands, which means that the Mg complex can be developed as a potential new anticancer drug.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.